Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02316847 · ClinicalTrials.gov registry record · Phase 2
An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray.
A Phase 2 study, sponsored by Acorda Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 126
- Enrollment target
NCT02316847 is a Phase 2 study that was terminated before completion, run by Acorda Therapeutics. The registered enrollment target is 126 participants.
The verdict
NCT02316847, a Phase 2 study, was terminated before completion, sponsored by Acorda Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 126 participants
- Enrollment target
Study Summary
This study will assess long-term safety and tolerability of repeat dose diazepam nasal spray in adolescents and adults with cluster seizures, with a focus on potential local effects (changes in nasal mucosa, olfaction, and taste).
Interventions
- DRUG diazepam nasal spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2014-12 |
| Est. Completion | 2016-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02316847
The ClinicalTrials.gov registry entry for NCT02316847 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acorda Therapeutics, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which diazepam nasal spray is the first listed.
NCT02316847 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02316847 about?
NCT02316847 is a clinical study titled "An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray.". This study will assess long-term safety and tolerability of repeat dose diazepam nasal spray in adolescents and adults with cluster seizures, with a focus on potential local effects (changes in nasal mucosa, olfaction, and taste).
What is the current status of trial NCT02316847?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 126 participants. The study started on 2014-12. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02316847?
The interventions under investigation include: diazepam nasal spray (DRUG).
Who is sponsoring clinical trial NCT02316847?
This trial is sponsored by Acorda Therapeutics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.